Abstract
Many neurodegenerative diseases are late onset diseases, associated with aggregation of proteins, implying that aged cells are more susceptible to proteotoxic stress. It is known that with aging, there is a decline in the functionality of chaperone networks and on the other hand, accumulation of damaged proteins occurs. Together, this has a cumulative effects on cellular protein homeostasis. Several studies have revealed that availability of DNAJ proteins, the cochaperones to the Hsp70 machine, could be a rate-limiting factor in handling diseased proteins within the cell. In this review, we highlight how DNAJ proteins can affect aggregation of disease-causing proteins, if and how this depends on their function as Hsp70 co-chaperones, and how much this depends on the type of protein causing the disease. Finally, we will discuss the five known degenerative diseases that are linked to mutations in individual DNAJ members and what mechanism may underlie these DNAJ chaperonopathies.
Keywords: Protein aggregation diseases, DNAJ proteins, neurodegeneration, Hsp70, chaperonopathies, protein quality control
Current Topics in Medicinal Chemistry
Title:DNAJ Proteins and Protein Aggregation Diseases
Volume: 12 Issue: 22
Author(s): Vaishali Kakkar, Louis C. B. Prins and Harm H. Kampinga
Affiliation:
Keywords: Protein aggregation diseases, DNAJ proteins, neurodegeneration, Hsp70, chaperonopathies, protein quality control
Abstract: Many neurodegenerative diseases are late onset diseases, associated with aggregation of proteins, implying that aged cells are more susceptible to proteotoxic stress. It is known that with aging, there is a decline in the functionality of chaperone networks and on the other hand, accumulation of damaged proteins occurs. Together, this has a cumulative effects on cellular protein homeostasis. Several studies have revealed that availability of DNAJ proteins, the cochaperones to the Hsp70 machine, could be a rate-limiting factor in handling diseased proteins within the cell. In this review, we highlight how DNAJ proteins can affect aggregation of disease-causing proteins, if and how this depends on their function as Hsp70 co-chaperones, and how much this depends on the type of protein causing the disease. Finally, we will discuss the five known degenerative diseases that are linked to mutations in individual DNAJ members and what mechanism may underlie these DNAJ chaperonopathies.
Export Options
About this article
Cite this article as:
Kakkar Vaishali, C. B. Prins Louis and H. Kampinga Harm, DNAJ Proteins and Protein Aggregation Diseases, Current Topics in Medicinal Chemistry 2012; 12 (22) . https://dx.doi.org/10.2174/1568026611212220004
DOI https://dx.doi.org/10.2174/1568026611212220004 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Medicinal Chemistry Advancement in Life-Threatening Diseases
The current issue will highlight concise reports that specify ground-breaking insights, including the novel discovery of drug targets and their action mechanism or drugs of novel classes. These are projected to encourage medicinal chemistry future efforts to address the most challenging medical needs. The current issue highlights further efforts to ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Dendritic Cell Immunotherapy for Acute Inflammatory Diseases
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry The Role of B-Lymphocyte Stimulator in Neuroendocrine Tumors: Correlation with Tumor Differentiation, Disease status and the Presence of Metastases
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Repair and Translesion DNA Polymerases as Anticancer Drug Targets
Anti-Cancer Agents in Medicinal Chemistry Nucleic Acid-Based Aptamers: Applications, Development and Clinical Trials
Current Medicinal Chemistry Pathophysiogenesis of Mesial Temporal Lobe Epilepsy: Is Prevention of Damage Antiepileptogenic?
Current Medicinal Chemistry Therapeutic Potential of Cannabinoids in Schizophrenia
Recent Patents on CNS Drug Discovery (Discontinued) Approaches to Optimize Gene Therapy for the Treatment of Hematologic Malignancies: Overcoming the Obstacles
Current Gene Therapy Role of COL4A1 in Basement-Membrane Integrity and Cerebral Small-Vessel Disease. The COL4A1 Stroke Syndrome
Current Medicinal Chemistry The Role of Intracellular 35-Cyclic Adenosine Monophosphate (cAMP) in Atherosclerosis
Current Vascular Pharmacology Modelling the Impact of Antiretroviral Therapy on the Epidemic of HIV
Current HIV Research Pulmonary Complications After Congenital Heart Surgery
Current Respiratory Medicine Reviews PPARγ Pro12Ala Polymorphism in HIV-1-Infected Patients with HAARTRelated Lipodystrophy
Current HIV Research Susceptibility Genes for the Side Effect of Antipsychotics on Body Weight and Obesity
Current Drug Targets ESVS Guidelines: Section B - Diagnosis and Investigation of Patients with Carotid Stenosis
Current Vascular Pharmacology Altered Mesolimbic Dopamine System in THC Dependence
Current Neuropharmacology A Review on Hematopoietic Stem Cell Treatment for Epilepsy
CNS & Neurological Disorders - Drug Targets The Psychopharmacology of Appetite: Targets for Potential Anti-Obesity Agents
Current Medicinal Chemistry - Central Nervous System Agents Pharmacotherapy of Abdominal Aortic Aneurysms
Current Vascular Pharmacology Insights into the Molecular Mechanism of hERG1 Channel Activation and Blockade by Drugs
Current Medicinal Chemistry The Pluripotential Effects of Hypolipidemic Treatment for Polycystic Ovary Syndrome (PCOS): Dyslipidemia, Cardiovascular Risk Factors and Beyond
Current Pharmaceutical Design